Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
Patrick Schnegelsberg, Chief Executive Officer, will be presenting at
the MarketReach America Conference on June 21st at the Mt. Washington
Conference Center in Baltimore, Maryland.
Patrick Schnegelsberg will provide an update on the Company's
pipeline to treat cancer and discuss VitiGam, GammaCan's lead program
to treat malignant melanoma.
About VitiGam:
VitiGam is a second generation intravenous IgG-based product and a
first-in-class anti-cancer immunotherapy. GammaCan plans on having
VitiGam to enter phase I/II testing under a US IND in the near future
and the Company recently held a pre-IND meeting with the FDA. VitiGam
is being designed to target metastatic melanoma patients with Stage
III and IV melanoma. VitiGam is an IgG product that is different from
standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.
About GammaCan:
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Giv'at Shmuel, Israel at 972 3 5774475 or
toll free 1-866-308-0396 (from North America).
About MarketReach America:
MarketReach America is an award winning program that brings
leading edge Israeli tech companies to Maryland for investment and
strategic partnering opportunities. MarketReach America is a program
of the Maryland/Israel Development Center (MIDC), an alliance of the
Maryland Department of Business and Economic Development, Israel's
Ministry of Industry and Trade and The ASSOCIATED: Jewish Community
Federation of Baltimore. The program is conducted in partnership with
The Trendlines Group, the MIDC representative in Israel. The MIDC is
the only organization that has been awarded three successive grants
from the bi-national US-Israel Science and Technology Foundation to
run such a partnering program.
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, inability to hire appropriate staff to develop the
technology, unforeseen technical difficulties in developing the
technology, inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early stage medical
research and development companies filed with the SEC on EDGAR.